Physician profile
David C Rubin
NPI 1598759326
$9,209.70
in general payments reported to CMS, 2019-2025
41 companies · $2,440 in 2025
The $2,440 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,027 · 2020: $654 · 2021: $171 · 2022: $629 · 2023: $1,523 · 2024: $1,766 · 2025: $2,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,728.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,272.32 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $812.62 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $797.61 | 2019-2025 | Lifevest |
| Amgen INC. | $711.82 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $651.16 | 2019-2025 | |
| Aop Health US, LLC | $559.68 | 2025 | Rapiblyk |
| Janssen Pharmaceuticals, INC | $553.40 | 2019-2024 | Xarelto |
| Scpharmaceuticals INC. | $499.13 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $476.64 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.85 | 2019-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $275.01 | 2024-2025 | Assure Wcd |
| Medtronic, INC. | $268.29 | 2021-2024 | Aurora Ev-Icd Mri Surescan, Micra, Linq II |
| Gilead Sciences, INC. | $207.60 | 2019 | |
| Boston Scientific Corporation | $197.70 | 2019-2025 | Watchman Flx, Watchman |
| Regeneron Healthcare Solutions, INC. | $177.03 | 2019-2025 | Evkeeza |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $165.84 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $141.66 | 2025 | |
| Abbott Laboratories | $141.59 | 2022-2023 | Amplatzer Amulet, Thoratec Heartmate 3 Lvas Implant Kit, Aveir |
| Silk Road Medical, INC. | $125.00 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Novo Nordisk INC | $99.03 | 2024-2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $82.13 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $79.64 | 2024-2025 | Nexletol |
| Atricure, INC. | $65.60 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $38.50 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $35.90 | 2022-2023 | Verquvo |
| Preventice Services, LLC | $34.59 | 2019 | |
| Lundbeck LLC | $33.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.65 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $25.82 | 2025 | Opsynvi |
| Medtronic Vascular, INC. | $24.90 | 2019 | |
| Amarin Pharma, INC. | $24.59 | 2019 | |
| Cvrx, INC. | $24.56 | 2024 | Barostim Neo System |
| Lantheus Medical Imaging, INC. | $21.67 | 2023 | Definity |
| Philips North America LLC | $21.62 | 2024 | (5091) Amb Mon & Diag Und |
| Bridgebio Pharma, INC. | $20.26 | 2025 | Attruby |
| Irhythm Technologies, INC. | $18.55 | 2023 | Zio Xt Patch |
| Heartflow, INC. | $18.30 | 2025 | |
| Astellas Pharma US INC | $15.15 | 2019 | |
| Cook Medical LLC | $13.85 | 2019 | |
| Biotronik INC. | $13.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.